The Future of Gene Patents: Making Sense of the Supreme Court’s Decision in the Myriad Case; plus, Analyzing Policy Impacts on Biotechnology Innovation Using Patent Data Workshop – Mar 13, 14 2014, Washington DC

Join us on Capitol Hill for two days of lively discussion prompted by the Supreme Court’s June 13 2013 ruling in the Association for Molecular Pathology (AMP) v. Myriad Genetics – hosted by the University of Alberta, McGill University, and the Duke University Institute for Genome Science and Policy.

On the morning of March 13th attend a Congressional Briefing on Capital Hill hosted by the office of Congresswoman and Democratic National Committee chairwoman Debbie Wasserman Schultz. This public session will present a general overview of Supreme Court’s decision in AMP v. Myriad and repercussions in the US context, especially with regard to patient access to healthcare, and will be attended by politicians, staffers, and other key stakeholders. Following this, there will be a series of more focussed panels for international scholars and practitioners around the world to discuss the implications of the Supreme Court Ruling more broadly.

On Mar 14th attend a workshop targeted at academics, examining methodology for analyzing policy impacts on biotechnology innovation using patent data. The focus will be on sharing and dissecting methods and data approaches, challenges and creative solutions.

For more information: email us at paceomics2@gmail.com